WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Elif Günay* and Meltem Türkmen

ABSTRACT

Background: Hidradenitis suppurativa is a chronic inflammatory and disrupting disease of pilosebaceous unit. Its advanced grade forms are treated with Adalimumab, an anti-TNF agent. Adalimumab is safe and effective on hidradenitis suppurativa both with original molecule and its biosimilar. Objectives: Presenting efficacy and safety of both original and biosimilar forms of adalimumab on 300 hidradenitis suppurativa patients. Methods: 300 hidradenitis suppurativa with Hurley stage II and III patients using adalimumab therapy followed for 108 week in our clinic and their data were analyzed retrospectively.with the Friedman test followed by post hoc Dunn's multiple comparison test. Comparison of variables in two groups at the same time point was performed with the Mann Whitney U test. Results: Reaching HiSCR was 78 % at week 108 and no side effect was detected on patients.. Dermatological life quality index of patients was improved from 25.2 to 6.8 on the end of 108 week period. Conclusion: Adalimumab is safe, effective on Hidradenitis suppurativa patients and provides improvement on quality of life both with original and biosimilar forms.